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Drug-eluting stents and late outcomes
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Despite rapid advances in the applicability and
safety of coronary angioplasty over its first quarter
century of existence, restenosis following initially
successful revascularisation remained a seemingly
insoluble limitation of the procedure. Given the
long-standing frustration associated with lesion
recurrence, the dramatic reductions in restenosis
recently brought about by drug-eluting stents
(DES) have been met with unconcealed enthusiasm
among interventional cardiologists. Despite the lack
of long-term outcome data, DES has been rapidly
adopted into clinical practice, often for clinical indi-
cations and lesion subsets exceeding those tested
in the clinical trials. In spite of their cost (approxi-
mately triple that of bare metal stents), over 90%
of coronary stents used in many hospitals are DES,
with the result that in only a few years DES have
been implanted in an estimated 6 million individu-
als worldwide, with total sales exceeding 5 billion
US dollars per year.
While the short-term effectiveness of DES for
preventing restenosis remains indisputable, three
separate studies presented at the recent World
Congress of Cardiology in Barcelona with follow-up
extending up to 4 years have raised unexpected
concerns regarding the long-term safety of the cur-
rently available first-generation sirolimus and pa-
clitaxel-eluting stents. These studies, two of which
represented meta-analyses of randomised DES tri-
als and the third an examination of a large DES reg-
istry, suggested that the short-term restenosis be-
nefits of currently available DES might be counter-
balanced by an increased likelihood of more
clinically devastating late events such as stent-
-thrombosis, myocardial infarction, and perhaps
cardiac and even non-cardiac mortality.
From a mechanistic perspective, these results
lend support to the contention that DES may be so
effective in inhibiting stent endothelialisation and
neointimal hyperplasia formation that they leave the
stent vulnerable to thrombosis for months or pos-
sibly even years following implantation, necessitat-
ing prolonged or perhaps indefinite dual anti-plate-
let therapy with aspirin and a thienopyridine. Within
the DES registry study presented in Barcelona, late
thrombosis continued to occur in a linear fashion at
a rate of 0.6% per year throughout the three-year
study period, without evidence of levelling-off at
3 years. Moreover, 77% of stent thrombosis episodes
occurred among patients not on dual anti-platelet
therapy at the time of the event.
Given the potential concerns raised by these
findings, should our current practices regarding
DES implantation be altered and, if so, how? Clear-
ly, prospective long-term follow-up studies of var-
ious DES platforms, drugs types and release kinet-
ics need to be performed to better understand the
true incidence of late thrombosis and the effects of
these parameters on thrombosis rates. Subgroup
analyses should be undertaken to better understand
what lesion types, procedural variables and patient
co-morbidities predict better or worse long-term
outcomes following DES. Studies to determine the
optimal duration of dual anti-platelet therapy follow-
ing DES implantation are essential. In addition,
a better understanding is needed of the mechanism
by which late thrombosis (and possibly even excess
late non-cardiac mortality) occurs after DES place-
ment. Because this information will, however, take
years to accumulate, we are left with the issue of
how to treat patients today.
Pending further data, the following principles
regarding the selection of patients for DES seem
reasonable:
— DES placement should be limited to clinical
scenarios and lesion subsets with proven
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indications. Prudence would dictate avoiding
techniques that are known to be associated
with higher rates of stent thrombosis, such as
many forms of bifurcation DES placement.
Likewise, the temptation should be strictly
avoided to place a DES at the site of an angio-
graphically moderate stenosis that is not prov-
en to be flow-limiting, which may be enticing
to some interventionalists because of the low
likelihood of restenosis;
— impeccable stent implantation technique, in-
cluding proper stent sizing and expansion rel-
ative to the true vessel diameter, is obligatory
and may play a role in reducing thrombosis risk.
Limiting total stent length to that of the lesion
length may also reduce the propensity for late
stent thrombosis;
— for patients in whom prolonged (or possibly in-
definite) dual anti-platelet therapy is potentially
not safe or desirable, DES should probably be
avoided. This may include individuals requiring
chronic warfarin therapy, those with increased
bleeding risk or prior major haemorrhagic
events, and those who require non-cardiac sur-
gery necessitating discontinuation of anti-
platelet therapy within the next year;
— DES use should probably also be avoided
among individuals with a high potential for non-
compliance with their anti-platelet therapy.
While drug-eluting stents have revolutionised
the practice of interventional cardiology in a very
short period of time, the concerns raised regard-
ing late thrombosis must be considered real. More
data is needed regarding the true incidence, tim-
ing, and clinical sequelae of late events following
DES placement. As time progresses, the issue of
late thrombosis will be better understood and, it
must be hoped, can be overcome by modifications
to the DES design. In the meantime, prudent use
and careful weighing up of the risks and benefits
of DES implantation to individual patients is war-
ranted.
